Naltrexone detection in your system depends on the formulation taken (oral tablet vs. extended-release injection), individual metabolic factors, and the type of drug test administered. The standard 50 mg oral dose is typically cleared from the body within 4 to 6 days, while the extended-release injectable form (Vivitrol) remains active for approximately 28 to 30 days. Understanding how naltrexone behaves in your system matters for medication planning, drug testing scenarios, and coordinating care during opioid addiction treatment or alcohol recovery.
Key Takeaways
- Oral naltrexone clears in 4 to 6 days: Standard 50 mg tablets have a half-life of about 4 hours for the parent compound and 13 hours for the active metabolite 6β-naltrexol — full elimination occurs within roughly five half-lives.
- Vivitrol lasts approximately 30 days: The 380 mg extended-release intramuscular injection maintains therapeutic blood levels for about 28 days, with detectable traces lingering longer.
- Naltrexone is not an opioid: Standard 5-panel and 10-panel drug tests do not screen for naltrexone, and it will not produce a positive result for opioids, opiates, or controlled substances.
- Precipitated withdrawal is a real risk: You must be opioid-free for 7 to 10 days (short-acting opioids) or 10 to 14 days (long-acting opioids like methadone) before starting naltrexone.
- Liver function drives clearance: Naltrexone is metabolized in the liver, so impaired liver function, age, and concurrent medications can extend detection windows significantly.
- Professional supervision matters: Starting naltrexone outside of medically supervised detox carries serious health risks, including severe withdrawal symptoms.
If you or a loved one is considering naltrexone as part of recovery, our admissions team can walk you through the process — call (866) 890-9573 to speak confidentially with our clinical staff.
What Is Naltrexone and How Does It Work?
Naltrexone is a non-addictive opioid antagonist approved by the U.S. Food and Drug Administration for the treatment of opioid use disorder (OUD) and alcohol use disorder (AUD). It works by binding to opioid receptors in the brain without activating them, effectively blocking the euphoric and sedative effects of opioids like heroin, fentanyl, and oxycodone.
For people in heroin addiction treatment or recovering from fentanyl dependency, naltrexone removes the reinforcing reward of relapse. For those in alcohol rehab, it reduces cravings and the pleasurable effects of drinking by modulating the brain’s endogenous opioid system.
Unlike methadone or buprenorphine, naltrexone has no abuse potential and produces no opioid effects. It is sold under the brand names ReVia and Depade (oral) and Vivitrol (extended-release injectable).
Naltrexone Detection Times by Test Type
The detection window for naltrexone varies significantly depending on the formulation and the testing method. Most standard workplace and clinical drug screens do not test for naltrexone, but specialized laboratory assays can identify the parent compound and its primary metabolite.
| Test Type | Oral Naltrexone (50 mg) | Vivitrol (380 mg IM) | Notes |
|---|---|---|---|
| Urine | 4 to 6 days | Up to 30 days | Specialized LC-MS/MS assay required |
| Blood | 24 hours (parent), 48–72 hours (metabolite) | 28 to 30 days | Therapeutic monitoring rare |
| Saliva | 1 to 4 days | Not commonly tested | Limited clinical use |
| Hair | Up to 90 days | Up to 90 days | Detects long-term use only |
Standard immunoassay drug panels — including the federally mandated SAMHSA 5-panel — do not include naltrexone. Disclosing your prescription to a Medical Review Officer (MRO) before testing is still recommended in workplace contexts to avoid any confusion about other medications you may be taking.
How Naltrexone Is Metabolized
Naltrexone undergoes extensive first-pass metabolism in the liver, where it is rapidly converted into its primary active metabolite, 6β-naltrexol. Both compounds exert opioid-blocking effects, though 6β-naltrexol is significantly less potent than the parent drug.
According to the National Library of Medicine’s MedlinePlus database, oral naltrexone reaches peak plasma concentration within one hour of ingestion. The parent compound has a relatively short half-life of about 4 hours, while 6β-naltrexol persists longer at approximately 13 hours.
The extended-release injectable formulation (Vivitrol) bypasses first-pass metabolism, releasing naltrexone gradually from a polymer microsphere matrix over approximately 30 days. This produces stable blood concentrations and improves medication adherence — a known weakness of daily oral dosing.
Half-Life Breakdown: Oral vs. Extended-Release
Understanding the half-life of each naltrexone formulation helps clarify how long the medication remains active and detectable.
| Formulation | Dose | Half-Life | Time to Full Elimination | Duration of Action |
|---|---|---|---|---|
| Oral naltrexone (parent) | 50 mg | ~4 hours | ~20 hours | 24 hours |
| Oral 6β-naltrexol (metabolite) | 50 mg | ~13 hours | ~65 hours | 24–36 hours |
| Vivitrol (extended-release) | 380 mg IM | 5–10 days | 25–50 days | ~28 days |
| Low-dose naltrexone (LDN) | 1.5–4.5 mg | ~4 hours | ~20 hours | 12–24 hours |
Pharmacologically, “elimination” and “effect” are not identical. Naltrexone’s opioid-blocking effect outlasts measurable blood concentrations because of how tightly it binds to mu-opioid receptors. A single 50 mg oral dose blocks opioid effects for approximately 24 hours, while a 100 mg dose can extend that blockade to 48 hours.
Factors That Affect How Long Naltrexone Stays in Your System
Individual variation in how the body processes naltrexone can be substantial. Several biological and behavioral factors influence clearance rates and detection windows.
| Factor | Impact on Clearance | Clinical Significance |
|---|---|---|
| Liver function | Impaired liver = 2–3x longer clearance | Liver disease may contraindicate use |
| Age | Older adults clear 25–40% slower | Reduced hepatic enzyme activity |
| Body weight & composition | Higher body fat = slower clearance | Affects Vivitrol distribution |
| Hydration status | Dehydration slows urinary excretion | Minor but measurable effect |
| Concurrent medications | CYP enzyme interactions possible | Disclose all medications |
| Kidney function | Reduced GFR slows excretion | Dose adjustment may be needed |
| Duration of use | Chronic use produces minor accumulation | Particularly relevant for Vivitrol |
| Genetic enzyme variation | CYP2C9 polymorphisms affect metabolism | Explains individual differences |
People with active liver disease, hepatitis, or significantly elevated liver enzymes require careful evaluation before starting naltrexone. Our dual diagnosis treatment program includes comprehensive medical workup precisely because co-occurring health conditions change medication decisions.
The Precipitated Withdrawal Risk
This is the single most important safety issue with naltrexone, and it warrants its own section. Because naltrexone displaces opioids from receptor sites with greater affinity than the opioids themselves, starting it too soon after opioid use can trigger immediate, severe withdrawal — known clinically as precipitated withdrawal.
The minimum opioid-free interval before starting naltrexone is:
- 7 to 10 days for short-acting opioids (heroin, oxycodone, hydrocodone, morphine, fentanyl)
- 10 to 14 days for long-acting opioids (methadone, extended-release oxycodone)
- Up to 14 days for individuals with chronic, high-dose opioid use histories
Symptoms of precipitated withdrawal include severe nausea, vomiting, diarrhea, sweating, muscle cramping, agitation, anxiety, and in some cases hemodynamic instability requiring emergency intervention. This is why naltrexone induction belongs in a supervised medical detox setting — not at home, not from a pill bottle handed over after an ER visit.
A naloxone challenge test is sometimes performed before naltrexone induction. A clinician administers a small dose of naloxone (a short-acting antagonist) and observes for any withdrawal signs. If none appear within 20 to 30 minutes, the patient is considered safe to start naltrexone.
Naltrexone and Drug Testing: What to Expect
A common concern among patients prescribed naltrexone — particularly those returning to work or navigating probation requirements — is whether the medication will appear on a drug test or cause a false positive.
Naltrexone does not produce positive results on standard immunoassay drug panels, including the SAMHSA-5, expanded 10-panel, or 12-panel screens used in most workplace and clinical contexts. This is because naltrexone is structurally distinct from the opioids and opiates these tests are designed to detect.
The Substance Abuse and Mental Health Services Administration (SAMHSA) confirms that naltrexone has no abuse potential and is not classified as a controlled substance. Patients should still inform their prescribing physician and any treating clinicians about their naltrexone use, especially before surgery — opioid pain management is substantially affected by active naltrexone blockade.
If a specialized panel specifically testing for naltrexone is ordered (rare outside of medication adherence monitoring in research settings), a valid prescription resolves the result through standard MRO review.
Medical Review Officer (MRO) Process and Workplace Protections
For people in recovery, the workplace drug testing landscape has shifted meaningfully in recent years. Under federal Department of Transportation rules and most state workplace testing programs, an MRO must verify any prescription medication detected on a drug screen before reporting a result to the employer.
If naltrexone use is somehow flagged — which is unusual but possible with specialized panels — the MRO contacts the employee privately, verifies the prescription with the prescribing clinician, and reports the result as negative to the employer. The employer never learns the specific medication.
Employees in safety-sensitive positions (commercial driving, aviation, healthcare) may face additional scrutiny, but medication-assisted treatment for substance use disorder is increasingly protected under the Americans with Disabilities Act (ADA). The U.S. Equal Employment Opportunity Commission has taken multiple enforcement actions against employers who terminated employees for legitimate MAT prescriptions, including naltrexone.
If you are starting naltrexone as part of a structured aftercare plan and have workplace testing concerns, our clinical team can help you understand your rights and coordinate documentation with your employer’s MRO.
Naltrexone for Alcohol Use Disorder vs. Opioid Use Disorder
While the pharmacology is the same across indications, the clinical use of naltrexone differs significantly between alcohol and opioid use disorders.
For alcohol use disorder, naltrexone reduces craving and the rewarding effects of drinking. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) lists naltrexone among first-line medications for AUD, often used alongside cognitive behavioral therapy and behavioral interventions. Patients can begin oral naltrexone for AUD without a prolonged abstinence period — alcohol does not interact with naltrexone the way opioids do.
For opioid use disorder, naltrexone serves as a relapse prevention tool after complete detoxification. The required opioid-free period before induction makes it less practical for some patients than buprenorphine, but for those who complete medically supervised detox, Vivitrol’s 30-day duration provides a powerful relapse safeguard.
The “Sinclair Method” — using oral naltrexone an hour before drinking to extinguish the reward response — has gained attention as an alternative AUD protocol, though it remains less commonly prescribed than abstinence-based approaches.
Naltrexone Side Effects and What to Expect
Understanding the common side effects helps set realistic expectations for patients starting therapy. Most side effects are mild and resolve within the first two weeks of treatment.
Common side effects include nausea (the most frequently reported), headache, dizziness, fatigue, insomnia, anxiety, and mild abdominal discomfort. Vivitrol can additionally cause injection site reactions including pain, induration, and occasionally sterile abscess formation.
Serious but rare risks include hepatotoxicity (liver injury), which is why baseline and periodic liver function testing is standard during naltrexone therapy. Depression and suicidal ideation have been reported, particularly in early treatment — our emotion regulation and mental health support is integrated into every treatment plan precisely because medications work best when paired with clinical care.
Anyone experiencing yellowing of the skin or eyes, dark urine, severe abdominal pain, or worsening mood while on naltrexone should contact their prescriber immediately.
When to Seek Professional Help
Naltrexone is not a standalone solution. It is a powerful adjunct to comprehensive addiction treatment that includes therapy, peer support, and long-term recovery planning. Starting naltrexone without proper medical assessment, supervised detox, and an integrated treatment plan can be ineffective at best and dangerous at worst.
If you are considering naltrexone or have been prescribed it without adequate clinical support, our admissions team can help you build a plan. Refine Recovery’s Los Angeles facility provides medically supervised detox, residential treatment, and aftercare planning under one roof — with the clinical depth to safely initiate medication-assisted treatment when appropriate.
Call (866) 890-9573 to speak with our admissions team, or verify your insurance coverage to begin the process. Recovery doesn’t wait for the perfect moment — it begins the moment you reach out.
Frequently Asked Questions
Does naltrexone show up on a drug test? No. Standard 5-panel and 10-panel drug tests do not screen for naltrexone, and it will not cause a false positive for opioids. Specialized laboratory assays can detect it, but these are uncommon outside of research and medication adherence monitoring.
Can I drink alcohol while taking naltrexone? Naltrexone does not produce a disulfiram-like reaction with alcohol (it won’t make you sick like Antabuse). However, it significantly reduces the pleasurable effects of drinking, which is one of its therapeutic mechanisms for alcohol use disorder.
How long after stopping naltrexone can I take opioids? For oral naltrexone, opioid receptor blockade typically resolves within 72 hours after the last dose. For Vivitrol, full receptor availability returns approximately 30 days after the last injection. Never combine opioids with active naltrexone — this can lead to opioid overdose as patients attempt to overcome the blockade.
Is naltrexone addictive? No. Naltrexone has no abuse potential, no euphoric effects, and produces no withdrawal syndrome when discontinued. It is not a controlled substance.
How is Vivitrol different from oral naltrexone? Vivitrol is an intramuscular injection given once every 28 to 30 days, providing continuous opioid blockade. Oral naltrexone is a daily tablet. Vivitrol eliminates daily adherence concerns but requires monthly clinical visits and is significantly more expensive.
